Chiral carbon nanomaterial for preventing and treating tobacco mosaic virus and preparation method and application thereof

Abstract

The application belongs to the technical field of carbon nanomaterial application, and particularly relates to chiral carbon nanomaterial for preventing and treating tobacco mosaic virus and a preparation method and application thereof. The application mainly solves the problem of poor virus prevention and treatment effect caused by easy inactivation and inability to continuously act of carbon nanomaterial in the existing method for preventing and treating plant virus based on carbon nanomaterial. The application relates to D-penicillamine modified carbon dots, which can destroy the protein shell of tobacco mosaic virus under right circular polarized light irradiation, inactivate the tobacco mosaic virus, and thus lose the infectivity, so as to achieve the purpose of preventing and treating tobacco mosaic virus. The application has the advantages of high stability, sustainable action and excellent virus prevention and treatment effect.

Description

Technical Field

[0001] This invention belongs to the field of carbon nanomaterial application technology, specifically relating to a chiral carbon nanomaterial for preventing and controlling tobacco mosaic virus, its preparation method and application. Background Technology

[0002] Tobacco mosaic virus (TMV) is a plant virus that seriously harms tobacco production. Tobacco plants infected with this virus are severely stunted, grow slowly, fail to flower and bear fruit normally, and are prone to fruit drop; many fail to germinate. Tobacco mosaic virus is widespread and increasingly serious in most tobacco-growing areas, with field incidence rates exceeding 50% in epidemic years. Tobacco mosaic virus not only affects tobacco growth and development and reduces leaf yield, but also severely impacts the appearance and internal quality of tobacco leaves, reducing the economic benefits for tobacco farmers and becoming a major obstacle to tobacco production. Therefore, the prevention and control of tobacco mosaic virus has always been a crucial issue in tobacco production.

[0003] Carbon dots (CDs), as a novel type of carbon-based nanomaterial, are near-spherical zero-dimensional semiconductor nanocrystals with diameters ranging from 2 to 10 nm. Due to their diverse physicochemical properties and advantages such as good biocompatibility, low cost, eco-friendliness, ease of modification, and high stability, they have attracted widespread research interest in recent years. Carbon dots exhibit good biocompatibility, allowing them to enter cells via endocytosis without affecting cellular function. Furthermore, the surface of carbon dots can be modified with various functional groups, exhibiting rich properties after modification with organic, inorganic, polymeric, and bioactive substances. Therefore, fabricating carbon dots into specific drug carriers has become an important direction for the development and application of carbon dots.

[0004] Existing methods for controlling plant viruses based on carbon nanomaterials, such as the patent application number 202211520960.1, disclose a carbon-based nanomaterial for delivering dsRNA as a nucleic acid carrier, its preparation method, and its application. This carbon-based nanomaterial is obtained by modifying carbon nitride with polyethyleneimine to obtain a nanomaterial with surface spikes. It can load double-stranded RNA (dsRNA) derived from plant viruses through electrostatic adsorption, solving the shortcomings of current delivery carrier preparation processes, such as low nucleic acid loading capacity, poor safety, and difficulty in penetrating plant cell walls. However, dsRNA is susceptible to attack by RNases in the cellular environment, leading to dsRNA degradation and causing the carbon nanomaterial to easily become inactive and unable to maintain its effect, resulting in poor virus control efficacy.

[0005] In summary, existing methods for controlling plant viruses based on carbon nanomaterials suffer from problems such as the easy inactivation of carbon nanomaterials and the inability to maintain their effect, resulting in poor virus control efficacy. Summary of the Invention

[0006] The technical problem this invention aims to solve is that existing methods for controlling plant viruses based on carbon nanomaterials suffer from poor virus control due to the easy inactivation and lack of sustained action of carbon nanomaterials. This invention provides a chiral carbon nanomaterial for controlling tobacco mosaic virus, its preparation method, and its application. This invention has the advantages of high stability, sustained action, and excellent virus control effect.

[0007] To address the aforementioned technical problems, this application provides the following technical solution:

[0008] This invention provides a method for preparing chiral carbon nanomaterials for preventing and controlling tobacco mosaic virus, comprising the following steps:

[0009] S1: Add sucrose and urea to water and mix. Then react at 150-170℃ for 2-4 hours to obtain reaction solution A.

[0010] S2: The reaction solution A is filtered, dialyzed, and then freeze-dried to obtain carbon dot powder;

[0011] S3: Mix the carbon dot powder, D-penicillamine and water and react them at 90-100℃ for 10-14h under a nitrogen atmosphere to obtain reaction solution B;

[0012] S4: The reaction solution B is purified to obtain chiral carbon nanomaterials for preventing and controlling tobacco mosaic virus.

[0013] Preferably, in step S1, the high-temperature reaction is carried out in a high-pressure hydrothermal reactor.

[0014] Preferably, in step S1, the mass ratio of sucrose to urea is 1-10:1-10.

[0015] Preferably, in step S2, the dialysis time is 4-6 days and the freeze-drying time is 3-5 days.

[0016] Preferably, in step S3, the mass ratio of carbon dot powder to D-penicillamine is 1-10:1-10.

[0017] The D-penicillamine is 3,3-dimethyl-D(-)-cysteine, with the chemical formula C5H. 11 NO2S.

[0018] Preferably, in step S4, the purification method is to mix reaction solution B and isopropanol and then centrifuge for 8-12 minutes.

[0019] The present invention also provides a chiral carbon nanomaterial for preventing and controlling tobacco mosaic virus prepared by the above preparation method.

[0020] Preferably, the chiral carbon nanomaterial for preventing tobacco mosaic virus has a particle size of 1-10 nm.

[0021] The present invention also provides a drug for preventing and controlling tobacco mosaic virus, which is obtained by resuspending the above-mentioned chiral carbon nanomaterials for preventing and controlling tobacco mosaic virus in a buffer solution (0.01M, pH=7.4).

[0022] Chiral carbon nanomaterials for controlling tobacco mosaic virus can destroy the protein coat of tobacco mosaic virus and inactivate it under irradiation with right-handed circularly polarized light (RCP), thereby losing its infectivity and achieving the purpose of controlling tobacco mosaic virus.

[0023] Furthermore, the drug for preventing tobacco mosaic virus is used by irradiation with right-handed circularly polarized light (RCP).

[0024] The technical solution of the present invention has the following advantages compared with the prior art:

[0025] This invention possesses the advantages of high stability, sustained action, and excellent virus control efficacy. The D-penicillamine-modified carbon dots described in this invention have a particle size matching the diameter of the tubular cavity of tobacco mosaic virus (4 nm). Under irradiation with right-handed circularly polarized light (RCP), they can directly enter the tubular cavity and catalyze the hydrolysis of amide bonds at specific sites on the protein coat, destroying the protein coat and inactivating it, thereby losing its infectivity and achieving the purpose of controlling tobacco mosaic virus. This invention remains stable after virus inactivation and can continuously act on tobacco mosaic virus, demonstrating the advantages of high stability, sustained action, and excellent virus control efficacy. Attached Figure Description

[0026] Figure 1 The image shows a transmission electron microscope (TEM) image of the D-penicillamine-modified carbon dots prepared in Example 1.

[0027] Figure 2 The images show TEM images of D-penicillamine-modified carbon dots from Examples 1-3 after irradiation with right-handed circularly polarized light (RCP), linearly polarized light (LP), and left-handed circularly polarized light (LCP) for 6 hours, applied to tobacco mosaic virus.

[0028] Figure 3 The images show Western blots of tobacco mosaic virus formed after D-penicillamine-modified carbon dots in Examples 1-3 were irradiated with RCP, LP, and LCP for 6 hours.

[0029] Figure 4 The images show TEM images of the L-penicillamine-modified carbon dots used in Examples 4-6 after 6 hours of irradiation with RCP, LP, and LCP on tobacco mosaic virus.

[0030] Figure 5The images show Western blots of tobacco mosaic virus formed after 6 hours of irradiation with RCP, LP, and LCP by L-penicillamine-modified carbon dots in Examples 4-6.

[0031] Figure 6 The images are TEM images of the D-penicillamine-modified carbon dots prepared in Examples 1, 12-15, corresponding to Examples 12, 1, 13, 14, and 15 from left to right. Detailed Implementation

[0032] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, so that those skilled in the art can better understand and implement the present invention. However, the embodiments described are not intended to limit the present invention.

[0033] Example 1

[0034] This embodiment provides a chiral carbon nanomaterial for preventing and controlling tobacco mosaic virus, its preparation method, and its application, as detailed below:

[0035] 5g of sucrose and 1.67g of urea were dissolved in 60mL of deionized water and transferred to an autoclave. The mixture was reacted at 160℃ for 3 hours to obtain reaction solution I. Reaction solution I was filtered, and the filtrate was dialyzed in ultrapure water for 5 days to remove small molecules, yielding reaction solution II. Reaction solution II was frozen in a freeze dryer for 4 hours and then vacuum dried for about 4 days until the ice sublimated completely, yielding a dark brown carbon dot powder.

[0036] 0.5 g of carbon dot powder and 0.5 g of D-penicillamine powder were transferred to a three-necked flask containing 35 mL of ultrapure water. The mixture was reacted at 95 °C for 12 hours under a nitrogen atmosphere to obtain reaction solution III. Reaction solution III was purified by centrifugation with isopropanol at room temperature for 10 minutes, and then resuspended in PBS solution (0.01 M, pH = 7.4) to obtain dispersion I. The morphology of the prepared carbon dots was observed by TEM imaging, as shown... Figure 1 As shown. Tobacco mosaic virus was resuspended in PBS solution (0.01M, pH=7.4) to a final concentration of 1.5 mg / mL. -1 Dispersion system II was obtained.

[0037] Mixture I was prepared by mixing equal amounts of 30 μL of dispersion system I and 30 μL of dispersion system II. Mixture I was first irradiated under sunlight for 3 days, then transferred to right-handed circularly polarized light (RCP) irradiation using a 532 nm laser as the light source for 6 hours. The inactivation rate (%) of tobacco mosaic virus was obtained by circular dichroism (CD) spectroscopy, and its morphology was observed based on TEM images and Western blot analysis. Figure 2 and Figure 3 As shown.

[0038] Example 2

[0039] This embodiment provides a chiral carbon nanomaterial for preventing and controlling tobacco mosaic virus, its preparation method, and its application. Similar to Example 1, the difference lies in replacing right-handed circularly polarized light (RCP) with linearly polarized light (LP). The inactivation rate (%) of tobacco mosaic virus is finally obtained by CD spectroscopy, and its morphology is observed based on TEM images and Western blot analysis. Figure 2 and Figure 3 As shown.

[0040] Example 3

[0041] This embodiment provides a chiral carbon nanomaterial for the prevention and control of tobacco mosaic virus, its preparation method, and its application. Similar to Example 1, the difference lies in replacing right-handed circularly polarized light (RCP) with left-handed circularly polarized light (LCP). The inactivation rate (%) of tobacco mosaic virus is finally obtained by CD spectroscopy, and its morphology is observed based on TEM images and Western blot analysis. Figure 2 and Figure 3 As shown.

[0042] Example 4

[0043] This embodiment provides a chiral carbon nanomaterial for the prevention and control of tobacco mosaic virus, its preparation method, and its application. Similar to Example 1, the difference is that D-penicillamine is replaced with L-penicillamine. The inactivation rate (%) of tobacco mosaic virus is finally obtained by CD spectroscopy, and its morphology is observed based on TEM images and Western blot analysis. Figure 4 and Figure 5 As shown.

[0044] Example 5

[0045] This embodiment provides a chiral carbon nanomaterial for the prevention and control of tobacco mosaic virus, its preparation method, and its application. Similar to Example 2, the difference is that D-penicillamine is replaced with L-penicillamine. The inactivation rate (%) of tobacco mosaic virus is finally obtained by CD spectroscopy, and its morphology is observed based on TEM images and Western blot analysis. Figure 4 and Figure 5 As shown.

[0046] Example 6

[0047] This embodiment provides a chiral carbon nanomaterial for the prevention and control of tobacco mosaic virus, its preparation method, and its application. Similar to Example 3, the difference is that D-penicillamine is replaced with L-penicillamine. The inactivation rate (%) of tobacco mosaic virus is finally obtained by CD spectroscopy, and its morphology is observed based on TEM images and Western blot analysis. Figure 4 and Figure 5 As shown.

[0048] Example 7

[0049] This embodiment provides a chiral carbon nanomaterial for the prevention and control of tobacco mosaic virus, its preparation method and application. Similar to Example 1, the difference is that D-penicillamine is replaced with racemic penicillamine obtained by mixing equal amounts of D-penicillamine and L-penicillamine. Finally, the inactivation rate (%) of tobacco mosaic virus is obtained by CD spectroscopy.

[0050] Example 8

[0051] This embodiment provides a chiral carbon nanomaterial for the prevention and control of tobacco mosaic virus, its preparation method and application. Similar to Example 2, the difference is that D-penicillamine is replaced with racemic penicillamine obtained by mixing equal amounts of D-penicillamine and L-penicillamine. Finally, the inactivation rate (%) of tobacco mosaic virus is obtained by CD spectroscopy.

[0052] Example 9

[0053] This embodiment provides a chiral carbon nanomaterial for the prevention and control of tobacco mosaic virus, its preparation method and application. Similar to Example 3, the difference is that D-penicillamine is replaced with racemic penicillamine obtained by mixing equal amounts of D-penicillamine and L-penicillamine. Finally, the inactivation rate (%) of tobacco mosaic virus is obtained by CD spectroscopy.

[0054] Example 10

[0055] This embodiment provides a chiral carbon nanomaterial for the prevention and control of tobacco mosaic virus, its preparation method and application. Similar to Example 1, the difference is that 0.5g of carbon dot powder and 0.5g of D-penicillamine powder are replaced with 0.5g of D-penicillamine powder. Finally, the inactivation rate (%) of tobacco mosaic virus is obtained by CD spectroscopy.

[0056] Example 11

[0057] This embodiment provides a chiral carbon nanomaterial for the prevention and control of tobacco mosaic virus, its preparation method and application. Similar to Example 1, the difference is that 0.5g of carbon dot powder and 0.5g of D-penicillamine powder are replaced with 0.5g of carbon dot powder. Finally, the inactivation rate (%) of tobacco mosaic virus is obtained by CD spectroscopy.

[0058] Example 12

[0059] This embodiment provides a chiral carbon nanomaterial for preventing tobacco mosaic virus, its preparation method, and its application. Similar to Example 1, the difference is that 1.67g of urea is replaced with 2.0g of urea. The morphology of the prepared carbon dots is observed using TEM images. Figure 6 As shown in the figure. The inactivation rate (%) of tobacco mosaic virus was finally obtained by CD spectroscopy.

[0060] Example 13

[0061] This embodiment provides a chiral carbon nanomaterial for preventing tobacco mosaic virus, its preparation method, and its application. Similar to Example 1, the difference is that 1.67g of urea is replaced with 1.0g of urea. The morphology of the prepared carbon dots is observed using TEM images. Figure 6 As shown in the figure. The inactivation rate (%) of tobacco mosaic virus was finally obtained by CD spectroscopy.

[0062] Example 14

[0063] This embodiment provides a chiral carbon nanomaterial for preventing tobacco mosaic virus, its preparation method, and its application. Similar to Example 1, the difference is that 1.67g of urea is replaced with 0.5g of urea. The morphology of the prepared carbon dots is observed using TEM images. Figure 6 As shown in the figure. The inactivation rate (%) of tobacco mosaic virus was finally obtained by CD spectroscopy.

[0064] Example 15

[0065] This embodiment provides a chiral carbon nanomaterial for preventing tobacco mosaic virus, its preparation method, and its application. Similar to Example 1, the difference is that 1.67g of urea is replaced with 0.25g of urea. The morphology of the prepared carbon dots is observed using TEM images. Figure 6 As shown in the figure. The inactivation rate (%) of tobacco mosaic virus was finally obtained by CD spectroscopy.

[0066] The results obtained from the above embodiments 1-15 are shown in Tables 1-3.

[0067] Comparative Example 1

[0068] According to the patent application number 202211520960.1, a carbon-based nanomaterial for delivering dsRNA as a nucleic acid carrier and its preparation method were used to prepare TMV CP-nanomaterials, and TMV prevention and control experiments were conducted.

[0069] Comparative Example 2

[0070] This comparative example is similar to Comparative Example 1, except that: when preparing powdered carbon dot carbon nitride, the mass ratio of oxalic acid, calcium hydroxide, and sodium citrate is 1:0.5:1, TMV CP-nanomaterials are prepared, and TMV prevention and control experiments are conducted.

[0071] Comparative Example 3

[0072] This comparative example is similar to Comparative Example 1, except that: when preparing powdered carbon dot carbon nitride, the mass ratio of oxalic acid, calcium hydroxide, and sodium citrate is 1:1.5:1, TMV CP-nanomaterials are prepared, and TMV prevention and control experiments are conducted.

[0073] Comparative Example 4

[0074] This comparative example is similar to Comparative Example 1, except that: when preparing powdered carbon dot carbon nitride, the total mass ratio of urea and sodium citrate to oxalic acid is 1:0.1, TMV CP-nanomaterials are prepared, and TMV prevention and control experiments are conducted.

[0075] Comparative Example 5

[0076] This comparative example is similar to Comparative Example 1, except that: when preparing powdered carbon dot carbon nitride, the total mass ratio of urea and sodium citrate to oxalic acid is 1:1, TMV CP-nanomaterials are prepared, and TMV prevention and control experiments are conducted.

[0077] Effect Evaluation 1

[0078] exist Figure 1 In this study, the carbon dots modified with D-penicillamine have a particle size of 4 nm, which matches the diameter of the tubular cavity of tobacco mosaic virus (4 nm). Under the irradiation of right-handed circularly polarized light (RCP), they can directly enter the tubular cavity and catalyze the hydrolysis of amide bonds at specific sites on the protein coat, thereby destroying the protein coat and inactivating it, thus losing its infectivity and achieving the purpose of preventing and controlling tobacco mosaic virus.

[0079] Figure 2 The left image shows the complete shape of the protein. Figure 3 The depth of the Western blot in the medium under LCP irradiation was the same as that in the control group, indicating that the tobacco mosaic virus was not inactivated by the carbon dots modified by D-penicillamine 6 hours after LCP irradiation. Figure 2 The image located in the middle shows partially broken protein fragments. Figure 3 The Western blots under LP irradiation were of moderate depth, indicating that a small number of tobacco mosaic virus cells were inactivated by D-penicillamine-modified carbon dots 6 hours after LP irradiation. Figure 2 The right image in the image shows a large number of broken protein fragments. Figure 3 The Western blot was faintest under RCP irradiation, indicating that the tobacco mosaic virus was almost completely inactivated by D-penicillamine-modified carbon dots 6 hours after RCP irradiation. In summary, Figure 2 and Figure 3 This indicates that the carbon dots modified with D-penicillamine showed the best control effect against tobacco mosaic virus 6 hours after RCP irradiation.

[0080] Figure 4 The left image shows the complete shape of the protein. Figure 5 The depth of the Western blot in the RCP irradiated medium was the same as that in the control group, indicating that the tobacco mosaic virus was not inactivated by the carbon dots modified by L-penicillamine 6 hours after RCP irradiation. Figure 4 The image located in the middle shows partially broken protein fragments. Figure 5 The Western blots under LP irradiation were of moderate depth, indicating that a small number of tobacco mosaic virus cells were inactivated by L-penicillamine-modified carbon dots 6 hours after LP irradiation. Figure 4 The right image in the image shows a large number of broken protein fragments. Figure 5 The Western blot was faintest under LCP irradiation, indicating that the tobacco mosaic virus was almost completely inactivated by L-penicillamine-modified carbon dots 6 hours after LCP irradiation. In summary, Figure 4 and Figure 5 This indicates that L-penicillamine-modified carbon dots showed the best control effect against tobacco mosaic virus 6 hours after LCP irradiation.

[0081] Figure 6 This indicates that the carbon dot particle size decreases as the amount of urea added decreases. The carbon dot particle size prepared in Example 12 was 7 nm, the carbon dot particle size prepared in Example 1 was 4 nm, the carbon dot particle size prepared in Example 13 was 3 nm, the carbon dot particle size prepared in Example 14 was 2 nm, and the carbon dot particle size prepared in Example 15 was 1 nm.

[0082] The TMV CP-nanomaterials prepared in the above comparative example were used to conduct TMV prevention and control experiments, and the results are shown in Table 4.

[0083] Table 1 shows the inactivation rates of tobacco mosaic virus obtained by CD spectroscopy in Examples 1-9.

[0084]

[0085] Table 1 shows that carbon dots modified with different chiral penicillinamines exhibit selectivity for polarized light type. For D-penicillinamine-modified carbon dots, the highest inactivation rate against tobacco mosaic virus (Tobacco Mosaic Virus) and the best control effect were observed under RCP irradiation; the inactivation rate against Tobacco Mosaic Virus was zero under LCP irradiation, showing no control effect; and the control effect was weak under LP irradiation. For L-penicillinamine-modified carbon dots, the inactivation rate against Tobacco Mosaic Virus was zero under RCP irradiation, showing no control effect; the highest inactivation rate against Tobacco Mosaic Virus and the best control effect were observed under LCP irradiation; and the control effect was weak under LP irradiation. For racemic penicillinamine-modified carbon dots, the inactivation rate against Tobacco Mosaic Virus was zero under RCP, LP, and LCP irradiation, showing no control effect.

[0086] Meanwhile, Table 1 shows that the carbon dots modified with D-penicillamine exhibited the highest inactivation rate and best control effect against tobacco mosaic virus under RCP irradiation. Therefore, RCP was selected as the polarized light type in Examples 10-11, and D-penicillamine and RCP were selected as the penicillamine type and polarized light type in Examples 12-15 to obtain better experimental results.

[0087] Table 2 shows the inactivation rates of tobacco mosaic virus obtained by CD spectroscopy in Examples 10-11.

[0088]

[0089] Table 2 shows that penicillamine or carbon dots alone had a zero inactivation rate against tobacco mosaic virus and were ineffective in controlling it. Combined with Example 1, it is clear that only penicillamine-modified carbon dots can produce a control effect against tobacco mosaic virus.

[0090] Table 3 shows the inactivation rates of tobacco mosaic virus obtained by CD spectroscopy in Examples 1, 12-15.

[0091]

[0092] Combination Figure 6 As shown in Table 3, the carbon dot particle size decreases with decreasing urea content. In Example 12, the carbon dot particle size is 7 nm, which is larger than the diameter of the tubular cavity of tobacco mosaic virus (4 nm). Therefore, it cannot enter the tubular cavity to catalyze the hydrolysis of the protein coat and cannot inactivate the tobacco mosaic virus. In Example 1, the carbon dot particle size is 4 nm, which matches the diameter of the tubular cavity of tobacco mosaic virus (4 nm). It can directly enter the tubular cavity and catalyze the hydrolysis of amide bonds at specific sites on the protein coat, destroying the protein coat and inactivating it, thereby losing its infectivity and achieving the purpose of preventing and controlling tobacco mosaic virus. Although the carbon dot particle size in Examples 13-15 is smaller than the diameter of the tubular cavity of tobacco mosaic virus (4 nm), the matching degree decreases as the particle size decreases, resulting in the carbon dots easily escaping and the inactivation rate decreasing.

[0093] Table 4 shows the experimental results of TMV prevention and control using the TMV CP-nanomaterials prepared in Comparative Examples 1-5.

[0094]

[0095]

[0096] (The percentage of the leaf surface covered by lesions is categorized as follows: no lesions -, lesion area <10% - +, 10% ≤ lesion area ≤ 30% - ++, 30% ≤ lesion area ≤ 50% - +++, 50% ≤ lesion area ≤ 70% - ++++, lesion area > 70% - +++++)

[0097] Table 4 shows that the lesion area in Comparative Examples 2-5 was mostly higher than 30%, while the lesion area in Comparative Example 1 was around 10%. This indicates that existing methods for controlling plant viruses based on carbon nanomaterials are ineffective against tobacco mosaic virus. Compared to the comparative examples, the D-penicillamine-modified carbon dots in Example 1 showed an inactivation rate of over 90% against tobacco mosaic virus under RCP irradiation. Therefore, this invention demonstrates superior virus control efficacy.

[0098] Obviously, the above embodiments are merely illustrative examples for clear explanation and are not intended to limit the implementation. Those skilled in the art will recognize that other variations or modifications can be made based on the above description. It is neither necessary nor possible to exhaustively list all possible implementations here. However, obvious variations or modifications derived therefrom are still within the scope of protection of this invention.

Claims

1. A method for preparing chiral carbon nanomaterials for preventing and controlling tobacco mosaic virus, characterized in that, Includes the following steps: S1: Add sucrose and urea to water and mix them. Then react at 150-170℃ for 2-4 hours to obtain reaction solution A. In step S1, the mass ratio of sucrose to urea is 1-10:1-10. S2: The reaction solution A is filtered, dialyzed, and then freeze-dried to obtain carbon dot powder; S3: The carbon dot powder, D-penicillamine and water are mixed and reacted at 90-100℃ for 10-14 h under a nitrogen atmosphere to obtain reaction solution B; the mass ratio of carbon dot powder to D-penicillamine is 1-10:1-10. S4: The reaction solution B is purified to obtain chiral carbon nanomaterials for preventing and controlling tobacco mosaic virus.

2. The preparation method according to claim 1, characterized in that, In step S1, the high-temperature reaction is carried out in a high-pressure hydrothermal reactor.

3. The preparation method according to claim 1, characterized in that, In step S2, the dialysis time is 4-6 days and the freeze-drying time is 3-5 days.

4. The preparation method according to claim 1, characterized in that, In step S4, the purification method is to mix reaction solution B and isopropanol and then centrifuge for 8-12 min.

5. A chiral carbon nanomaterial for preventing tobacco mosaic virus prepared by the preparation method according to any one of claims 1-4.

6. The chiral carbon nanomaterial for preventing and controlling tobacco mosaic virus as described in claim 5, characterized in that, The chiral carbon nanomaterials used to prevent tobacco mosaic virus have a particle size of 1-10 nm.

7. A drug for preventing and controlling tobacco mosaic virus, characterized in that, The drug for preventing and treating tobacco mosaic virus is obtained by resuspending the chiral carbon nanomaterials for preventing and treating tobacco mosaic virus as described in claim 5 or 6 in a buffer solution.

8. The drug for controlling tobacco mosaic virus as described in claim 7, characterized in that, The drug for preventing tobacco mosaic virus is used by irradiating with right-handed circularly polarized light.

Images